Legend Biotech Corporation (LEGN) Income Statement
LEGN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLEGN revenue and net income
Where LEGN's revenue goes
2025Each bar shows an amount and its share of revenue. LEGN kept −28.8% of revenue as net income.
LEGN profit margins
LEGN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +64.0% | +106.4% | +68.8% | — |
| Gross profit | +58.1% | +129.1% | +52.6% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LEGN quarterly EPS vs estimates
Legend Biotech beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 11, 2026 (estimate $0.01).
LEGN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.03B | $627.2M | $285.1M | $117.0M | $68.8M | $75.0M | $61.8M | $49.1M | $23.6M |
| Cost of revenue | $408.1M | $234.6M | $144.2M | $65.4M | $313.3M | $232.2M | $0 | $0 | −$96,000 |
| Gross profit | $620.8M | $392.7M | $140.9M | $51.6M | $68.8M | $75.0M | $61.8M | $49.1M | $23.7M |
| Research & development | $414.7M | $413.5M | $382.2M | $335.6M | $313.3M | $232.2M | $161.9M | $60.6M | $8.2M |
| Sales, general & admin | $341.6M | $284.3M | $200.9M | $174.0M | $149.5M | $23.1M | $32.4M | $3.9M | $1.6M |
| Total operating expenses | $757.3M | $695.9M | $580.4M | $507.3M | $461.1M | $75.0M | $194.3M | $64.2M | $9.6M |
| Operating income | −$136.5M | −$303.2M | −$439.5M | −$455.6M | −$392.3M | −$313.3M | −$132.5M | −$1.5M | $13.8M |
| Interest income | $40.1M | $61.2M | $42.1M | $8.2M | $971,000 | $2.9M | $4.6M | $6.2M | — |
| Interest expense | $21.4M | $21.6M | $21.8M | $10.8M | $900,000 | $4.2M | $223,000 | $82,000 | $0 |
| Income before taxes | −$282.6M | −$158.1M | −$520.1M | −$445.7M | −$407.2M | −$308.3M | −$127.3M | −$1.6M | $13.8M |
| Income taxes | $14.2M | $18.9M | −$1.9M | $625,000 | −$3.6M | −$41.9M | −$25.7M | $1.2M | $4.5M |
| Net income | −$296.8M | −$177.0M | −$518.3M | −$446.3M | −$403.6M | −$266.4M | −$101.6M | −$2.8M | $9.4M |
| EBITDA | −$232.3M | −$113.2M | −$477.9M | −$416.5M | −$392.4M | −$298.2M | −$129.4M | $149,000 | $14.1M |
| EPS (diluted) | −$1.60 | −$0.96 | −$2.96 | −$2.53 | −$2.12 | −$1.96 | −$1.01 | −$0.03 | — |
| Gross margin | 60.3% | 62.6% | 49.4% | 44.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.4% |
| Operating margin | −13.3% | −48.3% | −154.1% | −389.4% | −570.0% | −417.8% | −214.4% | −3.1% | 58.4% |
| Net margin | −28.8% | −28.2% | −181.8% | −381.5% | −586.4% | −355.2% | −164.4% | −5.7% | 39.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $387.5M | $305.1M | $306.4M | $272.3M | $255.1M | $195.1M | $186.5M | $160.2M | $186.5M | $94.0M | $79.5M | $96.0M |
| Cost of revenue | $137.4M | $175.9M | $123.5M | $115.3M | $98.0M | $71.3M | $73.9M | $55.5M | $50.5M | $54.7M | $32.5M | $48.6M |
| Gross profit | $250.1M | $129.2M | $182.9M | $157.0M | $157.1M | $123.7M | $112.6M | $104.7M | $136.1M | $39.3M | $47.0M | $47.4M |
| Research & development | $96.0M | $86.0M | $101.3M | $113.1M | $98.3M | $101.9M | $104.4M | $95.5M | $112.6M | $101.0M | $105.7M | $95.9M |
| Sales, general & admin | $96.4M | $90.1M | $101.2M | $87.3M | $80.6M | $72.4M | $83.1M | $79.6M | $65.4M | $56.2M | $62.4M | $28.1M |
| Total operating expenses | $192.4M | $179.0M | $203.5M | $200.5M | $178.9M | $174.4M | $187.0M | $174.8M | $178.0M | $157.1M | $166.9M | $139.9M |
| Operating income | $57.7M | −$49.8M | −$20.6M | −$43.5M | −$21.9M | −$50.6M | −$74.4M | −$70.0M | −$42.0M | −$117.9M | −$119.8M | −$92.5M |
| Interest income | $5.6M | $7.3M | $8.0M | $9.7M | $10.4M | $12.1M | $13.7M | $16.6M | $17.0M | $13.9M | $17.3M | $18.4M |
| Interest expense | $200,000 | $5.5M | $5.5M | $5.6M | $5.2M | $5.1M | $5.2M | $5.5M | $5.5M | $5.5M | $5.8M | $5.7M |
| Income before taxes | $55.5M | −$53.1M | −$19.6M | −$39.1M | −$124.8M | −$99.1M | $40.5M | −$120.9M | −$18.0M | −$59.8M | −$146.8M | −$62.5M |
| Income taxes | $22.3M | $1.2M | $11.2M | $616,000 | $582,000 | $1.8M | $14.2M | $4.4M | $226,000 | $5,000 | −$2.0M | −$288,000 |
| Net income | $33.2M | −$54.3M | −$30.8M | −$39.7M | −$125.4M | −$100.9M | $26.3M | −$125.3M | −$18.2M | −$59.8M | −$144.8M | −$62.2M |
| EBITDA | $69.4M | −$32.0M | −$2.1M | −$33.2M | −$113.7M | −$88.9M | $52.5M | −$109.9M | −$7.1M | −$48.6M | −$135.6M | −$51.6M |
| EPS (diluted) | $0.09 | −$0.15 | −$0.16 | −$0.22 | −$0.68 | −$0.54 | $0.14 | −$0.68 | −$0.10 | −$0.32 | −$0.80 | −$0.34 |
| Gross margin | 64.5% | 42.3% | 59.7% | 57.7% | 61.6% | 63.4% | 60.4% | 65.4% | 73.0% | 41.8% | 59.2% | 49.3% |
| Operating margin | 14.9% | −16.3% | −6.7% | −16.0% | −8.6% | −26.0% | −39.9% | −43.7% | −22.5% | −125.4% | −150.8% | −96.4% |
| Net margin | 8.6% | −17.8% | −10.1% | −14.6% | −49.2% | −51.7% | 14.1% | −78.2% | −9.8% | −63.6% | −182.2% | −64.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LEGN's financial statements (latest annual report filed March 10, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LEGN financial results
In fiscal year 2025 (ended December 31, 2025), Legend Biotech reported revenue of $1.0 billion, up 64.0% from the year before. It had a net loss of $296.8 million, a net profit margin of −28.8%. Diluted earnings per share came to −$1.60. Over five years revenue grew at an average rate of 68.8% a year.
See the LEGN stock overview for the latest quote and news, or the LEGN chart for price history and technical indicators.
LEGN income statement FAQ
What is Legend Biotech's annual revenue?
Legend Biotech reported total revenue of $1.0 billion for fiscal year 2025, which ended on December 31, 2025. That was up 64.0% from $627.2 million the previous year.
Is Legend Biotech profitable?
No. Legend Biotech reported a net loss of $296.8 million in fiscal 2025, a net profit margin of −28.8%; its operating margin was −13.3%.
What is Legend Biotech's gross margin?
Legend Biotech's gross margin was 60.3% in fiscal 2025: for every $100 of revenue, Legend Biotech kept $60 after the direct cost of its products and services.
How much does Legend Biotech spend on research and development?
Legend Biotech spent $414.7 million on research and development in fiscal 2025, 40.3% of revenue.
How fast is Legend Biotech growing?
Revenue grew 68.8% a year on average over the last five fiscal years, from $75.0 million to $1.0 billion.
What are Legend Biotech's earnings per share?
Legend Biotech earned $-1.60 per diluted share in fiscal 2025, compared with $-0.96 a year earlier.
When will Legend Biotech report its next earnings?
Legend Biotech is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Legend Biotech's fiscal year end?
Legend Biotech's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 10, 2026.